Position in AKTS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$56,556,515
New position
Shares Held
3,161,348
first reported quarter
Ownership
5.72%
of shares outstanding
% of Portfolio
15.70%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Position in Biotechnology
Healthcare · as of Mar 31, 2026Blue Owl Capital Holdings LP holds $268,354,900 across 25 Biotechnology names. AKTS ranks #1 (21.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AKTS |
Aktis Oncology, Inc.
This page
|
3,161,348 | $56,556,515 | |
| 2 | LRMR |
Larimar Therapeutics, Inc.
|
7,120,007 | $32,040,031 | |
| 3 | ENGN |
enGene Therapeutics Inc.
|
4,416,353 | $30,075,363 | |
| 4 | CGEM |
Cullinan Therapeutics, Inc.
|
1,909,764 | $27,137,746 | |
| 5 | MPLT |
MapLight Therapeutics, Inc.
|
1,005,929 | $20,450,536 | |
| 6 | CMPX |
Compass Therapeutics, Inc.
|
2,941,525 | $15,560,667 | |
| 7 | CNTX |
Context Therapeutics Inc.
|
5,089,015 | $13,333,219 | |
| 8 | EYPT |
EyePoint, Inc.
|
912,594 | $11,763,336 |
All Filings in AKTS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $56,556,515 | 3,161,348 | Shares | Defined | 2026-05-14 | |
| 2026-03-31 | $56,556,515 | 3,161,348 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||